Retrospective observational study of adverse events (AEs) in women with ovarian cancer (OC) switching from olaparib capsules to tablets: U.S. health care claims database study

Abstract

Objective: Olaparib (Lynparza®) was first FDA-approved as a capsule (400 mg bd) for the treatment of women with BRCAm recurrent OC after ≥3 lines of therapy. To reduce pill burden, a tablet (300 mg bd) was approved for this indication, and for maintenance treatment in platinum-sensitive recurrent (PSR) OC, regardless of BRCAm status. Despite dosing and bioavailability differences between olaparib capsules and tablets, clinical trial results suggest similar efficacy and tolerability profiles; real-world data are of interest.